ArticleClinical rheumatology2026
Integrated bioinformatics and clinical validation reveals PRDX6 as a mitochondrial hub gene in systemic lupus erythematosus.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesPeroxiredoxin 6 (PRDX6), a potent antioxidant enzyme, has garnered considerable interest for its potential involvement in inflammatory diseases. However, the relationship between PRDX6 and SLE remains poorly understood. This study aims to elucidate the association between PRDX6 and SLE, providing insights into its potential role in disease mechanisms.
methodGene expression datasets (GSE50772, GSE61635) from the GEO database were merged and batch-corrected (sva, limma). DEGs were identified and SLE-associated gene modules were analyzed by weighted gene co-expression network analysis (WGCNA). Intersecting differentially expressed genes (DEGs), module genes, and MitoCarta3.0-defined mitochondria-associated DEGs, which were refined by LASSO, Random Forest, and SVM-RFE to select hub genes. The expression levels of PRDX6 in peripheral blood mononuclear cells (PBMCs) from SLE patients were measured by quantitative PCR and Western blot analysis.
resultsA total of 1581 DEGs (865 upregulated, 716 downregulated) were identified. WGCNA revealed a key module of 1615 genes; intersecting this module with DEGs and MitoCarta3.0 yielded 36 mitochondria-associated DEGs. Three machine learning methods narrowed these to 11 core genes, including PRDX6. The expression levels of PRDX6 were significantly lower in SLE PBMCs than in healthy controls, especially in active SLE. Patients with renal or joint involvement had lower PRDX6 levels. The mRNA levels of PRDX6 showed an inverse correlation with Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score.
conclusionsThis study suggested that PRDX6 might be a potential biomarker and exert protective effects by reducing oxidative stress in SLE. Key Points • IFI27 and PRDX6 serve as potential mitochondrial-related biomarkers in SLE. • PRDX6 is significantly downregulated in SLE. • PRDX6 is associated with SLEDAI score.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.